Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection

Georgia Fousteri, Jason R. Chan, Yanan Zheng, Chan Whiting, Amy Dave, Damien Bresson, Michael Croft, Matthias Von Herrath

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - Development of antigen-specific strategies to treat or prevent type 1 diabetes has been slow and difficult because of the lack of experimental tools and defined biomarkers that account for the underlying therapeutic mechanisms. RESEARCH DESIGN AND METHODS - The type 1 diabetes PhysioLab platform, a large-scale mathematical model of disease pathogenesis in the nonobese diabetic (NOD) mouse, was used to investigate the possible mechanisms underlying the efficacy of nasal insulin B:9-23 peptide therapy. The experimental aim was to evaluate the impact of dose, frequency of administration, and age at treatment on Treg induction and optimal therapeutic outcome. RESULTS - In virtual NOD mice, treatment efficacy was predicted to depend primarily on the immunization frequency and stage of the disease and to a lesser extent on the dose. Whereas low-frequency immunization protected from diabetes atrributed to Treg and interleukin (IL)-10 induction in the pancreas 1-2 weeks after treatment, high-frequency immunization failed. These predictions were confirmed with wet-lab approaches, where only low-frequency immunization started at an early disease stage in the NOD mouse resulted in significant protection from diabetes by inducing IL-10 and Treg. CONCLUSIONS - Here, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed. In silico modeling was able to streamline the experimental design and to identify the particular time frame at which biomarkers associated with protection in live NODs were induced. These results support the development and application of humanized platforms for the design of clinical trials (i.e., for the ongoing nasal insulin prevention studies).

Original languageEnglish
Pages (from-to)3148-3158
Number of pages11
JournalDiabetes
Volume59
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Nose
Immunization
Insulin
Inbred NOD Mouse
Type 1 Diabetes Mellitus
Interleukin-10
Research Design
Therapeutics
Biomarkers
Computer Simulation
Immunotherapy
Pancreas
Theoretical Models
Clinical Trials
Antigens

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Fousteri, G., Chan, J. R., Zheng, Y., Whiting, C., Dave, A., Bresson, D., ... Von Herrath, M. (2010). Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes, 59(12), 3148-3158. https://doi.org/10.2337/db10-0561

Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. / Fousteri, Georgia; Chan, Jason R.; Zheng, Yanan; Whiting, Chan; Dave, Amy; Bresson, Damien; Croft, Michael; Von Herrath, Matthias.

In: Diabetes, Vol. 59, No. 12, 12.2010, p. 3148-3158.

Research output: Contribution to journalArticle

Fousteri, G, Chan, JR, Zheng, Y, Whiting, C, Dave, A, Bresson, D, Croft, M & Von Herrath, M 2010, 'Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection', Diabetes, vol. 59, no. 12, pp. 3148-3158. https://doi.org/10.2337/db10-0561
Fousteri, Georgia ; Chan, Jason R. ; Zheng, Yanan ; Whiting, Chan ; Dave, Amy ; Bresson, Damien ; Croft, Michael ; Von Herrath, Matthias. / Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. In: Diabetes. 2010 ; Vol. 59, No. 12. pp. 3148-3158.
@article{fa98810a597f4472853459ed0bf2bec3,
title = "Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection",
abstract = "OBJECTIVE - Development of antigen-specific strategies to treat or prevent type 1 diabetes has been slow and difficult because of the lack of experimental tools and defined biomarkers that account for the underlying therapeutic mechanisms. RESEARCH DESIGN AND METHODS - The type 1 diabetes PhysioLab platform, a large-scale mathematical model of disease pathogenesis in the nonobese diabetic (NOD) mouse, was used to investigate the possible mechanisms underlying the efficacy of nasal insulin B:9-23 peptide therapy. The experimental aim was to evaluate the impact of dose, frequency of administration, and age at treatment on Treg induction and optimal therapeutic outcome. RESULTS - In virtual NOD mice, treatment efficacy was predicted to depend primarily on the immunization frequency and stage of the disease and to a lesser extent on the dose. Whereas low-frequency immunization protected from diabetes atrributed to Treg and interleukin (IL)-10 induction in the pancreas 1-2 weeks after treatment, high-frequency immunization failed. These predictions were confirmed with wet-lab approaches, where only low-frequency immunization started at an early disease stage in the NOD mouse resulted in significant protection from diabetes by inducing IL-10 and Treg. CONCLUSIONS - Here, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed. In silico modeling was able to streamline the experimental design and to identify the particular time frame at which biomarkers associated with protection in live NODs were induced. These results support the development and application of humanized platforms for the design of clinical trials (i.e., for the ongoing nasal insulin prevention studies).",
author = "Georgia Fousteri and Chan, {Jason R.} and Yanan Zheng and Chan Whiting and Amy Dave and Damien Bresson and Michael Croft and {Von Herrath}, Matthias",
year = "2010",
month = "12",
doi = "10.2337/db10-0561",
language = "English",
volume = "59",
pages = "3148--3158",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection

AU - Fousteri, Georgia

AU - Chan, Jason R.

AU - Zheng, Yanan

AU - Whiting, Chan

AU - Dave, Amy

AU - Bresson, Damien

AU - Croft, Michael

AU - Von Herrath, Matthias

PY - 2010/12

Y1 - 2010/12

N2 - OBJECTIVE - Development of antigen-specific strategies to treat or prevent type 1 diabetes has been slow and difficult because of the lack of experimental tools and defined biomarkers that account for the underlying therapeutic mechanisms. RESEARCH DESIGN AND METHODS - The type 1 diabetes PhysioLab platform, a large-scale mathematical model of disease pathogenesis in the nonobese diabetic (NOD) mouse, was used to investigate the possible mechanisms underlying the efficacy of nasal insulin B:9-23 peptide therapy. The experimental aim was to evaluate the impact of dose, frequency of administration, and age at treatment on Treg induction and optimal therapeutic outcome. RESULTS - In virtual NOD mice, treatment efficacy was predicted to depend primarily on the immunization frequency and stage of the disease and to a lesser extent on the dose. Whereas low-frequency immunization protected from diabetes atrributed to Treg and interleukin (IL)-10 induction in the pancreas 1-2 weeks after treatment, high-frequency immunization failed. These predictions were confirmed with wet-lab approaches, where only low-frequency immunization started at an early disease stage in the NOD mouse resulted in significant protection from diabetes by inducing IL-10 and Treg. CONCLUSIONS - Here, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed. In silico modeling was able to streamline the experimental design and to identify the particular time frame at which biomarkers associated with protection in live NODs were induced. These results support the development and application of humanized platforms for the design of clinical trials (i.e., for the ongoing nasal insulin prevention studies).

AB - OBJECTIVE - Development of antigen-specific strategies to treat or prevent type 1 diabetes has been slow and difficult because of the lack of experimental tools and defined biomarkers that account for the underlying therapeutic mechanisms. RESEARCH DESIGN AND METHODS - The type 1 diabetes PhysioLab platform, a large-scale mathematical model of disease pathogenesis in the nonobese diabetic (NOD) mouse, was used to investigate the possible mechanisms underlying the efficacy of nasal insulin B:9-23 peptide therapy. The experimental aim was to evaluate the impact of dose, frequency of administration, and age at treatment on Treg induction and optimal therapeutic outcome. RESULTS - In virtual NOD mice, treatment efficacy was predicted to depend primarily on the immunization frequency and stage of the disease and to a lesser extent on the dose. Whereas low-frequency immunization protected from diabetes atrributed to Treg and interleukin (IL)-10 induction in the pancreas 1-2 weeks after treatment, high-frequency immunization failed. These predictions were confirmed with wet-lab approaches, where only low-frequency immunization started at an early disease stage in the NOD mouse resulted in significant protection from diabetes by inducing IL-10 and Treg. CONCLUSIONS - Here, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed. In silico modeling was able to streamline the experimental design and to identify the particular time frame at which biomarkers associated with protection in live NODs were induced. These results support the development and application of humanized platforms for the design of clinical trials (i.e., for the ongoing nasal insulin prevention studies).

UR - http://www.scopus.com/inward/record.url?scp=78650061905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650061905&partnerID=8YFLogxK

U2 - 10.2337/db10-0561

DO - 10.2337/db10-0561

M3 - Article

C2 - 20864513

AN - SCOPUS:78650061905

VL - 59

SP - 3148

EP - 3158

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -